Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2023-02-14 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Portfolio company Disc Medicine announces $62.5 million financing
Share Issue/Capital Change Classification · 1% confidence The document is an announcement by Arix Bioscience PLC regarding its portfolio company, Disc Medicine, securing a $62.5 million financing round. The text explicitly mentions the dissemination of a 'Regulatory Announcement' and contains details about a securities purchase agreement, stock offerings, and SEC filings (Form S-3). This type of announcement, detailing fundraising, capital structure changes, and investment activity, directly aligns with the definition of a Capital/Financing Update (CAP). Although it references SEC filings, the core subject is the financing event itself, not the filing document (like a 10-K or a prospectus supplement, which would be classified differently). It is not a general regulatory filing (RNS) because it fits the specific 'CAP' category.
2023-02-14 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document explicitly details a 'PDMR notification & Director Shareholding' concerning a transaction (purchase of 200,000 Ordinary shares) by a Director and Chairman, Peregrine Moncreiffe. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly matches the definition for Director's Dealing (DIRS). The structure and content are typical of regulatory disclosures regarding insider transactions.
2023-02-06 English
Unaudited NAV for January 2023
Net Asset Value Classification · 1% confidence The document explicitly states 'Unaudited NAV for January 2023' and provides a table detailing the breakdown of the Net Asset Value (NAV) as of 31 January 2023, including the total NAV and NAV per share. This directly corresponds to the definition of Net Asset Value (NAV) updates, which is classified as 'NAV'. The document length is short (2583 chars) and it is a direct announcement of the figure, not an announcement about a forthcoming report.
2023-02-06 English
Unaudited NAV for December 2022
Net Asset Value Classification · 1% confidence The document explicitly announces the 'Unaudited NAV for December 2022' and presents a table detailing the breakdown of the Total NAV and NAV per share as of December 31, 2022. Furthermore, the metadata section includes 'Category Code: NAV'. This directly corresponds to the Net Asset Value (NAV) filing type.
2023-01-30 English
Board Change
Board/Management Information Classification · 1% confidence The document explicitly states 'Board Change' in the title and body. It announces that 'Dr Benny Soffer, Non-Executive Director, will step down from the Board'. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-01-26 English
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
Regulatory Filings Classification · 1% confidence The document is a press release disseminated via EQS Group, dated 05-Jan-2023, announcing a significant corporate transaction: the acquisition of portfolio company Twelve Bio by Ensoma, concurrent with an $85 million financing round for Ensoma, which Arix co-led. This announcement details investment activity, M&A, and capital structure changes related to Arix's portfolio. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it details a major transaction (acquisition/financing), it fits best under Capital/Financing Update (CAP) or M&A Activity (TAR). Given the dual nature (financing and acquisition), and the focus on capital raising ($85M financing), CAP is a strong candidate, but TAR (Merger/Takeover Activity) specifically covers acquisitions. Since the core news involves the acquisition of a portfolio company, TAR is the most precise fit for the M&A component, although CAP is also relevant. However, this is a standard press release format announcing corporate actions, which often falls under general Regulatory Filings (RNS) if a more specific category isn't perfect. Since TAR covers merger proposals/takeover bids, and this is an acquisition, I will classify it as TAR. If TAR were not available, RNS would be the fallback.
2023-01-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.